Oragenics Inc. (NYSE American: OGEN), a clinical-stage biopharmaceutical company focused on developing brain-targeted therapeutics, has announced significant progress in its Phase IIa feasibility trial of ONP-002 for mild traumatic brain injury (mTBI), along with updates on its U.S. regulatory pathway and its listing status on the NYSE American.
The company has dosed nine participants across three active Australian clinical sites: Alfred Health, Mackay, and Royal Adelaide Hospital. This advancement marks a key step in evaluating ONP-002, which is delivered via Oragenics' proprietary intranasal delivery platform. ONP-002 is being developed as a potential first-in-class treatment for concussion and mTBI, a condition with significant unmet medical need.
In parallel, Oragenics has received responses from the U.S. Food and Drug Administration (FDA) regarding its Type B meeting request briefing package, which was submitted in July 2026. The company is currently reviewing these responses and remains focused on submitting an Investigational New Drug (IND) application by the end of 2026. A successful IND submission would allow Oragenics to initiate clinical trials in the United States, potentially accelerating the development of ONP-002.
The company also disclosed that it received a deficiency letter from the NYSE American on August 26, 2026, related to stockholders' equity requirements under Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide. Oragenics has 45 days from receipt of the letter to submit a plan to regain compliance. The company intends to do so within the required timeframe. If the plan is accepted, Oragenics would be able to maintain its listing during a cure period, subject to periodic review, with a compliance deadline of February 25, 2028.
These updates come as Oragenics continues to advance its pipeline. The company's intranasal delivery platform has potential applications across multiple neurological conditions, including Parkinson's disease, Alzheimer's disease, PTSD, and anxiety disorders. By addressing significant unmet medical needs in neurological care, Oragenics aims to bring innovative therapies to patients.
The progression of the Phase IIa trial and the ongoing FDA engagement are critical milestones for Oragenics. The company's ability to navigate regulatory requirements and maintain its listing will be key to its future operations and investor confidence. The positive momentum in Australia, combined with the planned U.S. regulatory submission, underscores the company's commitment to advancing ONP-002.
Investors and stakeholders will be watching closely as Oragenics works to meet its stated goals. The company's next steps include submitting the IND application and addressing the NYSE American compliance plan, both of which are pivotal to its near-term trajectory.
For more information, visit the company's newsroom at https://nnw.fm/OGEN.
